Dexcom Inc (DXCM) concluded trading on Thursday at a closing price of $78.92, with 3.28 million shares of worth about $258.47 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -31.55% during that period and on December 05, 2024 the price saw a loss of about -2.58%. Currently the company’s common shares owned by public are about 390.60M shares, out of which, 385.55M shares are available for trading.
Stock saw a price change of 1.05% in past 5 days and over the past one month there was a price change of 14.38%. Year-to-date (YTD), DXCM shares are showing a performance of -36.40% which decreased to -32.66% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $62.34 but also hit the highest price of $142.00 during that period. The average intraday trading volume for Dexcom Inc shares is 4.25 million. The stock is currently trading 4.37% above its 20-day simple moving average (SMA20), while that difference is up 9.42% for SMA50 and it goes to -20.98% lower than SMA200.
Dexcom Inc (NASDAQ: DXCM) currently have 390.60M outstanding shares and institutions hold larger chunk of about 93.20% of that.
The stock has a current market capitalization of $30.83B and its 3Y-monthly beta is at 1.13. PE ratio of stock for trailing 12 months is 47.31, while it has posted earnings per share of $1.67 in the same period. Its PEG reads 2.20 and has Quick Ratio of 2.12 while making debt-to-equity ratio of 1.31. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DXCM, volatility over the week remained 2.99% while standing at 3.64% over the month.
Stock’s fiscal year EPS is expected to rise by 12.24% while it is estimated to increase by 19.51% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Robert W. Baird on July 26, 2024 offering a Neutral rating for the stock and assigned a target price range of between $161 and $80 to it. Coverage by JP Morgan stated Dexcom Inc (DXCM) stock as a Neutral in their note to investors on July 26, 2024, suggesting a price target of $75 for the stock. On May 30, 2024, Redburn Atlantic Initiated their recommendations, while on March 12, 2024, RBC Capital Mkts Initiated their ratings for the stock with a price target of $165. Stock get an Equal-weight rating from Morgan Stanley on May 30, 2023.